Cardiometabolic Health and Inflammatory Resolution (REX)
Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Emma Börgeson, PhD
- Phone Number: +46313423833
- Email: emma.borgeson@wlab.gu.se
Study Contact Backup
- Name: Per-Anders Jansson, MD, PhD
- Phone Number: +46313420000
- Email: Per-Anders.Jansson@wlab.gu.se
Study Locations
-
-
Vastra Gotaland
-
Gothenburg, Vastra Gotaland, Sweden, 41669
- Recruiting
- Gothenburg University
-
Contact:
- Emma Börgeson, PhD
- Phone Number: +46313420000
- Email: emma.borgeson@wlab.gu.se
-
Contact:
- Per-Anders Jansson, PhD, MD
- Phone Number: +46313420000
- Email: Per-Anders.Jansson@wlab.gu.se
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed signed consent has been obtained from the volunteer.
- The volunteer has a BMI greater than 18.5 kg/m2
Exclusion Criteria:
- The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.
- An MD determines that the individual is on too many medications to participate
- The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.
- The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)
- The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.
- The individual has some form of chronic inflammation.
- The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).
- The individual uses immunosuppressive drugs (eg, methotrexate).
- The individual regularly consumes fish oils (omega 3).
- The individual has significant gastrointestinal problems.
- The individual smokes or uses chewing tobacco.
- The individual has been drinking alcohol two days before the study visit.
- The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination.
- The individual does not follow instructions given in the research study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Lean and metabolically healthy
|
|
Lean and metabolically unhealthy
|
|
Overweight and metabolically healthy
|
|
Overweight and metabolically unhealthy
|
|
Obese and metabolically healthy
|
|
Obese and metabolically unhealthy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inflammatory status
Time Frame: 2027
|
The inflammatory status, defined as CRP levels and ability to respond to pro-resolving therapeutics, will be studied in all 6 groups
|
2027
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2019-04179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.